Lantern Pharma doses first patient in LP-300 trial expansion cohort

Lantern Pharma (LTRN) announced that the first patient has been dosed – as part of the expansion cohort – in Japan for its Phase 2 Harmonic clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer, or NSCLC, who have progressed after receiving treatment with tyrosine kinase inhibitors, or TKIs.